Raja Pullatt
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Raja Pullatt has a total of 105 co-authors. Here are the top co-authors by number of shared publications:
Fayez Shamoon
8 shared publicationsGary V. Heller
Gagnon Cardiovascular Institute, Morristown Medical Center, Morristown, NJ, USA
5 shared publications- Nirmal Guragai
Department of Cardiology, St Joseph Regional Medical Center, Paterson, NJ, USA
5 shared publications Rahul Vasudev
Department of Cardiology, St Joseph Regional Medical Center, Paterson, NJ, USA
5 shared publications- Rahul Vasudev
Hackensack University Medical Center, Hackensack, NJ
5 shared publications Abhijit Ghatak
Division of Cardiology, Hartford Hospital, Hartford, Connecticut Department of Psychology, Connecticut College, New London, Connecticut
3 shared publications
Latest Publications
- Open Access
- 2 November 2021
- Published by Greater Baltimore Medical Center in Journal of Community Hospital Internal Medicine Perspectives
- Vol. 11 (6) , 839-842
Management of Wolff-Parkinson-White syndrome in a patient with peripartum cardiomyopathy
Wolf-Parkinson-White (WPW) syndrome is a congenital heart condition in which the atrioventricular (AV) node is bypassed by an accessory pathway that connects the atria and ventricle directly along with symptoms of syncope or palpitations. WPW syndrome in patients with a history of peripartum cardiomyopathy (pregnancy-related cardiomyopathy) is associated with a high risk of morbidity and mortality secondary to failure of the pump and the conduction system of the heart. Management of these cases deals with arrhythmia and systolic heart failure, which becomes more challenging in pregnant patients as it requires treatment methods that minimize risks to the fetus. We report a case of a young female patient with WPW syndrome and peripartum cardiomyopathy presenting with symptomatic arrhythmias (tachycardia).
- 2 November 2021
- Published by Greater Baltimore Medical Center in Journal of Community Hospital Internal Medicine Perspectives
- Vol. 11 (6) , 839-842
Open AccessManagement of Wolff-Parkinson-White syndrome in a patient with peripartum cardiomyopathy
Wolf-Parkinson-White (WPW) syndrome is a congenital heart condition in which the atrioventricular (AV) node is bypassed by an accessory pathway that connects the atria and ventricle directly along with symptoms of syncope or palpitations. WPW syndrome in patients with a history of peripartum cardiomyopathy (pregnancy-related cardiomyopathy) is associated with a high risk of morbidity and mortality secondary to failure of the pump and the conduction system of the heart. Management of these cases deals with arrhythmia and systolic heart failure, which becomes more challenging in pregnant patients as it requires treatment methods that minimize risks to the fetus. We report a case of a young female patient with WPW syndrome and peripartum cardiomyopathy presenting with symptomatic arrhythmias (tachycardia).
- Open Access
- 10 June 2021
- Published by Springer Nature in Cureus
- Vol. 13 (6) , e15573
Does Baseline Diuretics Use Affect Prognosis in Patients With COVID-19?
The rapid emergence of coronavirus disease 2019 (COVID-19) has become the biggest healthcare crisis of the last century, resulting in thousands of deaths worldwide. There have been studies that evaluated the role of angiotensin-converting enzyme (ACE) inhibitors (ACEi) and angiotensin receptor blockers (ARBs) in treating patients with COVID-19. However, the prior use of diuretics and their effect on mortality in this setting remains unknown. The aim of the study was to evaluate the effect of diuretics in patients admitted with COVID-19. The current study was conducted between March 15, 2020, and April 30, 2020, during the COVID-19 pandemic in three different hospitals in Northern New Jersey, USA. The primary outcome was survival or in-hospital mortality from COVID-19 from the day of admission. The secondary outcome was severe or non-severe illness from COVID-19. This retrospective study included a total of 313 patients with a median age of 61.3 ± 14.6 years. There was a total of 68 patients taking diuretics at home and 245 patients who were not taking diuretics. There was a total of 39 (57.35%) deaths in patients taking diuretics as compared to 93 (37.96%) deaths in patients not taking diuretics (p-value 0.0042). Also, 54 (79.41%) patients who took diuretics had severe COVID-19 illness as compared to 116 (47.35%) who did not take diuretics (p-value <.0001). However, after adjusting for the confounding factors, there was no difference in mortality or severity of illness in COVID-19 patients taking diuretics at the time of admission. In conclusion, there was no effect of the baseline use of diuretics in the prognosis of COVID-19.
- 10 June 2021
- Published by Springer Nature in Cureus
- Vol. 13 (6) , e15573
Open AccessDoes Baseline Diuretics Use Affect Prognosis in Patients With COVID-19?
The rapid emergence of coronavirus disease 2019 (COVID-19) has become the biggest healthcare crisis of the last century, resulting in thousands of deaths worldwide. There have been studies that evaluated the role of angiotensin-converting enzyme (ACE) inhibitors (ACEi) and angiotensin receptor blockers (ARBs) in treating patients with COVID-19. However, the prior use of diuretics and their effect on mortality in this setting remains unknown. The aim of the study was to evaluate the effect of diuretics in patients admitted with COVID-19. The current study was conducted between March 15, 2020, and April 30, 2020, during the COVID-19 pandemic in three different hospitals in Northern New Jersey, USA. The primary outcome was survival or in-hospital mortality from COVID-19 from the day of admission. The secondary outcome was severe or non-severe illness from COVID-19. This retrospective study included a total of 313 patients with a median age of 61.3 ± 14.6 years. There was a total of 68 patients taking diuretics at home and 245 patients who were not taking diuretics. There was a total of 39 (57.35%) deaths in patients taking diuretics as compared to 93 (37.96%) deaths in patients not taking diuretics (p-value 0.0042). Also, 54 (79.41%) patients who took diuretics had severe COVID-19 illness as compared to 116 (47.35%) who did not take diuretics (p-value <.0001). However, after adjusting for the confounding factors, there was no difference in mortality or severity of illness in COVID-19 patients taking diuretics at the time of admission. In conclusion, there was no effect of the baseline use of diuretics in the prognosis of COVID-19.
- Open Access
- 1 January 2021
- Published by Korean Society of Echocardiography in Journal of Cardiovascular Imaging
- Vol. 29 (1) , 82-83
Non Visualization of the Cardiac Structures during Transesophageal Echocardiogram: Think Outside the Heart
Cedano J, et al. J Cardiovasc Imaging. 2019 Sep;28:e51. https://doi.org/10.4250/jcvi.2020.0065
- 1 January 2021
- Published by Korean Society of Echocardiography in Journal of Cardiovascular Imaging
- Vol. 29 (1) , 82-83
Open AccessNon Visualization of the Cardiac Structures during Transesophageal Echocardiogram: Think Outside the Heart
Cedano J, et al. J Cardiovasc Imaging. 2019 Sep;28:e51. https://doi.org/10.4250/jcvi.2020.0065
- Open Access
- 24 November 2020
- Published by Springer Nature in Cureus
- Vol. 12 (11)
A Rare Case of Myocarditis Mimicking ST-Elevation Myocardial Infarction
Myocarditis is caused by acute injury and inflammation of cardiac myocytes and is most commonly caused by a viral infection. Myocarditis remains a rare diagnosis and manifests with a wide spectrum of non-specific symptoms that include chest pain, dyspnea, and palpitations associated with electrocardiographic abnormalities that resemble that of ST-elevation myocardial infarction (STEMI). Therefore, clinical diagnosis is often challenging and is often misdiagnosed. We present a case of a 22-year-old male who presented with left-sided non-radiating chest pain associated with shortness of breath, elevated troponin of 3.2 ng/ml (<0.03 ng/ml). Electrocardiogram (ECG) and cardiac echocardiogram revealed ST-segment elevations in the anterolateral leads and an ejection fraction of 35%, respectively. The patient was initially suspected of having a STEMI; however, cardiac catheterization revealed non-obstructed coronary arteries. Due to elevated inflammatory markers, the patient was then started on colchicine for suspected myocarditis and had complete resolution of symptoms one week after. This case highlights that a high index of clinical suspicion and prompt diagnosis is necessary to prevent any delays in appropriate therapy for myocarditis.
- 24 November 2020
- Published by Springer Nature in Cureus
- Vol. 12 (11)
Open AccessA Rare Case of Myocarditis Mimicking ST-Elevation Myocardial Infarction
Myocarditis is caused by acute injury and inflammation of cardiac myocytes and is most commonly caused by a viral infection. Myocarditis remains a rare diagnosis and manifests with a wide spectrum of non-specific symptoms that include chest pain, dyspnea, and palpitations associated with electrocardiographic abnormalities that resemble that of ST-elevation myocardial infarction (STEMI). Therefore, clinical diagnosis is often challenging and is often misdiagnosed. We present a case of a 22-year-old male who presented with left-sided non-radiating chest pain associated with shortness of breath, elevated troponin of 3.2 ng/ml (<0.03 ng/ml). Electrocardiogram (ECG) and cardiac echocardiogram revealed ST-segment elevations in the anterolateral leads and an ejection fraction of 35%, respectively. The patient was initially suspected of having a STEMI; however, cardiac catheterization revealed non-obstructed coronary arteries. Due to elevated inflammatory markers, the patient was then started on colchicine for suspected myocarditis and had complete resolution of symptoms one week after. This case highlights that a high index of clinical suspicion and prompt diagnosis is necessary to prevent any delays in appropriate therapy for myocarditis.
- 13 August 2020
- Published by Wiley in Echocardiography
- Vol. 37 (9) , 1362-1365
The utility of bedside echocardiography in critically ill COVID‐19 patients: Early observational findings from three Northern New Jersey hospitals
Introduction: Cardiovascular complications related to coronavirus disease 2019 (COVID‐19) have led to the need for echocardiographic services during the pandemic. The present study aimed to identify the echocardiographic findings in hospitalized COVID‐19 patients and their utility in disease management.Methods: We included patients who were diagnosed with COVID‐19 using polymerase chain reaction and those who underwent echocardiographic examination during their hospitalization.Results: Altogether, 45 patients were evaluated. The mean age was 61.4 ± 12.2 years. Hypertension (n = 29, 64%) and diabetes mellitus (n = 25, 55%) were the most common comorbidities followed by congestive heart failure (n = 11, 24%), coronary artery disease (n = 9, 20%), and valvular heart disease (n = 3, 7%). Eight patients (18%) showed evidence of myocardial injury, as suggested by elevated troponin levels. Brain natriuretic peptide was elevated in 14 patients (36%), and 14 patients had left ventricular dysfunction in the form of reduced ejection fraction (31%). Right ventricular (RV) dilatation was observed in six patients, and five patients had reduced RV ejection fraction. RV pressure and volume overload were observed in three patients. RV thrombus was observed in one patient. Pulmonary pressure was elevated in 10 patients (24%).Conclusion: Two‐dimensional echocardiography can be an important bedside tool for the assessment of cardiovascular abnormalities and hemodynamic status of COVID‐19 patients.
- 13 August 2020
- Published by Wiley in Echocardiography
- Vol. 37 (9) , 1362-1365
The utility of bedside echocardiography in critically ill COVID‐19 patients: Early observational findings from three Northern New Jersey hospitals
Introduction: Cardiovascular complications related to coronavirus disease 2019 (COVID‐19) have led to the need for echocardiographic services during the pandemic. The present study aimed to identify the echocardiographic findings in hospitalized COVID‐19 patients and their utility in disease management.Methods: We included patients who were diagnosed with COVID‐19 using polymerase chain reaction and those who underwent echocardiographic examination during their hospitalization.Results: Altogether, 45 patients were evaluated. The mean age was 61.4 ± 12.2 years. Hypertension (n = 29, 64%) and diabetes mellitus (n = 25, 55%) were the most common comorbidities followed by congestive heart failure (n = 11, 24%), coronary artery disease (n = 9, 20%), and valvular heart disease (n = 3, 7%). Eight patients (18%) showed evidence of myocardial injury, as suggested by elevated troponin levels. Brain natriuretic peptide was elevated in 14 patients (36%), and 14 patients had left ventricular dysfunction in the form of reduced ejection fraction (31%). Right ventricular (RV) dilatation was observed in six patients, and five patients had reduced RV ejection fraction. RV pressure and volume overload were observed in three patients. RV thrombus was observed in one patient. Pulmonary pressure was elevated in 10 patients (24%).Conclusion: Two‐dimensional echocardiography can be an important bedside tool for the assessment of cardiovascular abnormalities and hemodynamic status of COVID‐19 patients.
- 1 July 2020
- Published by Taylor & Francis in Acta Cardiologica
- Vol. 76 (2) , 220-221
Unmasking of Brugada syndrome in a patient with Coronavirus disease 2019 (COVID-19)
(2020). Unmasking of Brugada syndrome in a patient with Coronavirus disease 2019 (COVID-19). Acta Cardiologica. Ahead of Print.
- 1 July 2020
- Published by Taylor & Francis in Acta Cardiologica
- Vol. 76 (2) , 220-221
Unmasking of Brugada syndrome in a patient with Coronavirus disease 2019 (COVID-19)
(2020). Unmasking of Brugada syndrome in a patient with Coronavirus disease 2019 (COVID-19). Acta Cardiologica. Ahead of Print.
- Open Access
- 1 June 2019
- Published by Oxford University Press (OUP) in European Heart Journal - Cardiovascular Imaging
- Vol. 20 (Supplement)
P284Pseudo Normalization Of Abnormal T- Waves As An Aid To Identify Reversible Perfusion Defects
Background: In patients with baseline ST segment depression and T wave inversion, EKG stress testing has a limited diagnostic role. In a few numbers of these patients, the baseline T wave abnormalities may return to normal during ischemia referred to as pseudonormalization of the T wave, the significance of this phenomena is unknown. The aim of this study to determine if T-wave pseudonormalization during exercise or pharmacological stress testing identified patients with myocardial ischemia as indicated by reversible perfusion defects.
- 1 June 2019
- Published by Oxford University Press (OUP) in European Heart Journal - Cardiovascular Imaging
- Vol. 20 (Supplement)
Open AccessP284Pseudo Normalization Of Abnormal T- Waves As An Aid To Identify Reversible Perfusion Defects
Background: In patients with baseline ST segment depression and T wave inversion, EKG stress testing has a limited diagnostic role. In a few numbers of these patients, the baseline T wave abnormalities may return to normal during ischemia referred to as pseudonormalization of the T wave, the significance of this phenomena is unknown. The aim of this study to determine if T-wave pseudonormalization during exercise or pharmacological stress testing identified patients with myocardial ischemia as indicated by reversible perfusion defects.
- 1 April 2019
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Quality and Outcomes
- Vol. 12 (Suppl_1)
Abstract 126: Putting Into Practice: American Heart Association 2017 Standards for Hospital Electrocardiographic Monitoring and Inappropriate Telemetry Use
Background: Initially hospital electrocardiographic monitoring (telemetry) was introduced for heart rate and rhythm monitoring in the CCU. It has expanded, but with the caveat of increased inappropriate use. In one study 1 of 236 admissions, 50% of the 745 monitoring days were not indicated by ACC/AHA guidelines. Similar studies 2 have been done, but these were done prior to the release of the 2017 AHA Updates on the Standards of Inpatient Electrocardiographic monitoring 3 . Our intent was to evaluate the power of education alone, and the ability thus to implement recent expert recommendations into current practice. Methods: A retrospective evaluation was done (chart review over 3 months) for patients admitted to telemetry units to then assess the appropriateness of telemetry usage. Intervention was through the education on the appropriate indications and duration of inpatient telemetry as per the “Update to Practice Standards for Electrocardiographic Monitoring in Hospital Settings 3 .” Education included providing the guidelines and indications to physicians/medical staff. After intervention, charts were reviewed over the next 3 months to evaluate for changes. The study was created as a cyclical/rolling study. Results: Out of the 166 charts reviewed from the pre intervention group, 61 involved patients on telemetry, and 14/61 (23%) was the percentage of inappropriate telemetry usage. In the post-intervention group, 248 charts reviewed, 94 involved patients on telemetry, and inappropriate telemetry usage was 14/94 (15%). The most common reasons for inappropriate telemetry use: hemodynamically stable GI bleed (6/28), alcohol withdrawal (4/28), and hypertensive urgency (6/28). Between the two groups there was an 8% decrease, showing more appropriate use of telemetry after intervention (statistical significance, p-value=0.2). Bed allocation however specifically improved along with several other end-points. Conclusion: The 8% decrease in the inappropriate telemetry usage created better bed allocation from the emergency department (ED) and led to decreased ED wait times and earlier transfers of patients from the intensive care unit. The overall results were in accordance with our expectations as we were aware of the limitations (length of study time, single intervention of education). However, the sole education of the AHA 2017 standards 3 led to desired trends of decreased in inappropriate telemetry use and opening several avenues to augment patient care and placement, liberation of multiple medical departments to deliver more focused care, and overall improvement in hospital work flow and cost-effectiveness. With interdepartmental efforts, use of technology, protocols and more, the current practices will become all the more likely to mirror the recommended standards. We thus plan to continue to move on to the further stages of our model to reveal the summative endpoints achieved.
- 1 April 2019
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Quality and Outcomes
- Vol. 12 (Suppl_1)
Abstract 126: Putting Into Practice: American Heart Association 2017 Standards for Hospital Electrocardiographic Monitoring and Inappropriate Telemetry Use
Background: Initially hospital electrocardiographic monitoring (telemetry) was introduced for heart rate and rhythm monitoring in the CCU. It has expanded, but with the caveat of increased inappropriate use. In one study 1 of 236 admissions, 50% of the 745 monitoring days were not indicated by ACC/AHA guidelines. Similar studies 2 have been done, but these were done prior to the release of the 2017 AHA Updates on the Standards of Inpatient Electrocardiographic monitoring 3 . Our intent was to evaluate the power of education alone, and the ability thus to implement recent expert recommendations into current practice. Methods: A retrospective evaluation was done (chart review over 3 months) for patients admitted to telemetry units to then assess the appropriateness of telemetry usage. Intervention was through the education on the appropriate indications and duration of inpatient telemetry as per the “Update to Practice Standards for Electrocardiographic Monitoring in Hospital Settings 3 .” Education included providing the guidelines and indications to physicians/medical staff. After intervention, charts were reviewed over the next 3 months to evaluate for changes. The study was created as a cyclical/rolling study. Results: Out of the 166 charts reviewed from the pre intervention group, 61 involved patients on telemetry, and 14/61 (23%) was the percentage of inappropriate telemetry usage. In the post-intervention group, 248 charts reviewed, 94 involved patients on telemetry, and inappropriate telemetry usage was 14/94 (15%). The most common reasons for inappropriate telemetry use: hemodynamically stable GI bleed (6/28), alcohol withdrawal (4/28), and hypertensive urgency (6/28). Between the two groups there was an 8% decrease, showing more appropriate use of telemetry after intervention (statistical significance, p-value=0.2). Bed allocation however specifically improved along with several other end-points. Conclusion: The 8% decrease in the inappropriate telemetry usage created better bed allocation from the emergency department (ED) and led to decreased ED wait times and earlier transfers of patients from the intensive care unit. The overall results were in accordance with our expectations as we were aware of the limitations (length of study time, single intervention of education). However, the sole education of the AHA 2017 standards 3 led to desired trends of decreased in inappropriate telemetry use and opening several avenues to augment patient care and placement, liberation of multiple medical departments to deliver more focused care, and overall improvement in hospital work flow and cost-effectiveness. With interdepartmental efforts, use of technology, protocols and more, the current practices will become all the more likely to mirror the recommended standards. We thus plan to continue to move on to the further stages of our model to reveal the summative endpoints achieved.